-2%
Dasanix (Dasatinib), which is primarily used for the treatment of Philadelphia chromosome-positive (Ph+) leukemia.Â
Dasatinib works by inhibiting multiple kinases (e.g., BCR-ABL, SRC family kinases) and can overcome resistance to prior treatments like Imatinib. Key properties include:
- Absorption: Peaks in 0.5 to 6 hours.
- Distribution: Binds ~96% to plasma proteins.
- Metabolism: Primarily metabolized by CYP3A4.
- Excretion: Mostly via feces (~85%).
- Treatment of adult patients with:
- Newly diagnosed Ph+ CML in the chronic phase.
- Advanced phases of CML or Ph+ ALL with resistance or intolerance to prior therapy.
- Treatment of pediatric patients (1 year and older) with:
- Chronic phase Ph+ CML.
- Newly diagnosed Ph+ ALL (in combination with chemotherapy).